TriCelX files FDA IND for XytriX in chronic traumatic encephalopathy

By AI, Created 6:53 AM UTC, May 18, 2026, /AGP/ – TriCelX has submitted a Phase 1/2 IND to the FDA for XytriX, its allogeneic UC-MSC biotherapeutic for adults with confirmed or probable chronic traumatic encephalopathy. The filing could open the first CTE-directed biotherapeutic program under the 2024 Blast Overpressure Safety Act and includes requests for RMAT and Breakthrough Therapy designations.

Why it matters: - TriCelX is trying to move XytriX into the first FDA-reviewed CTE biotherapeutic program since Congress passed the Blast Overpressure Safety Act in December 2024. - The filing matters because CTE has no FDA-approved treatment or disease-modifying therapy. - TriCelX says the program is designed to fit the federal care-access and monitoring structure created for blast-related brain injury.

What happened: - TriCelX submitted a Phase 1/2 Investigational New Drug application to the U.S. Food and Drug Administration for XytriX, a proprietary allogeneic UC-MSC biotherapeutic for adults with confirmed or probable CTE. - The submission went to FDA’s Center for Biologics Evaluation and Research, Office of Tissues and Advanced Therapies. - TriCelX also requested Regenerative Medicine Advanced Therapy designation and Breakthrough Therapy designation. - The company says this is the first IND filing for a CTE-directed biotherapeutic since BOSA became law. - The same XytriX drug substance was previously reviewed in TriCelX’s knee osteoarthritis IND, which received a “Study May Proceed” determination on April 22, 2026.

The details: - CTE is described as a progressive, fatal tauopathy caused by repetitive head impacts and blast overpressure exposure. - The disease typically progresses through cognitive decline, behavioral dysregulation, psychiatric collapse, and dementia. - Postmortem evidence from the Boston University CTE Center identified CTE as a cause of dementia in a study of 614 cases. - TriCelX says XytriX is an off-the-shelf allogeneic biotherapeutic made from ethically sourced donated human birth tissue. - The company says the cells cross the blood-brain barrier through an SDF-1α/CXCR4 homing mechanism and migrate to damaged brain regions. - TriCelX says the product’s therapeutic secretome includes BDNF, GDNF, NGF, VEGF, IGF-1, IL-10, and TGF-β. - The proposed mechanisms include immunomodulation, reduced neuroinflammation, microglial polarization, neurotrophic support, blood-brain barrier repair, tau reduction, and remyelination. - XytriX is manufactured at TriCelX’s FDA-registered cGMP/cGTP-compliant facility in Frisco, Texas. - Each batch is tested for sterility, endotoxin, identity, and viability. - The product is cryopreserved in a serum-free, animal-component-free medium. - TriCelX says the therapy requires no HLA matching, no autologous harvest, and no specialized neurosurgical infrastructure for intravenous use. - The proposed Phase 1/2 study is open-label, dose-escalation, and single-center. - The trial plans to enroll about 24 base subjects across three dose cohorts, with an optional 12-subject expansion for total enrollment of up to 36. - Participants receive treatment cycles at Months 0, 3, and 6, with follow-up through Month 24. - Cognitive efficacy will be measured with the Neuropsychological Assessment Battery, with secondary endpoints including MoCA, CTE Core Assessment Protocol, PCL-5, NPI, C-SSRS, SF-36, and plasma biomarkers. - Biomarker testing will use the Quanterix Simoa HD-X platform. - An independent DSMB will oversee safety. - Abdul Baker, MD, FAANS, FACS, FCNS, is the principal investigator, and the study will run at Baylor Scott & White Sports Therapy & Research Center in Frisco, Texas. - TriCelX says the program’s diagnostic and response-assessment model draws on DIAGNOSE CTE biomarker findings and the NINDS Consensus Traumatic Encephalopathy Syndrome criteria. - The company’s CTE filing follows its prior knee osteoarthritis IND, and TriCelX says the two programs together make XytriX a dual-indication platform.

Between the lines: - TriCelX is trying to position XytriX as more than a one-disease asset by linking CTE, blast injury, and broader tauopathy biology. - The company is also tying the program to federal military health policy, which could help with future study access and funding pathways. - That strategy puts regulatory progress, military medicine, and biomarker science at the center of the commercial story.

What’s next: - FDA will review the IND and the company’s RMAT and Breakthrough Therapy requests. - TriCelX says it intends to engage USAMMDA, SOCOM, CDMRP, BARDA, the Defense Health Agency, NICoE, the VA Cooperative Studies Program, and NIH. - If the designations are granted, TriCelX says the program could get faster FDA interaction, rolling review, priority review, and other accelerated pathways. - The company is also looking toward future Phase 2 and Phase 3 pivotal studies in blast-related CTE.

The bottom line: - TriCelX is taking an aggressive regulatory swing at one of neurology’s hardest problems: a fatal disease with no approved treatment and no standard way to slow it.